SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 8.27% Passive Stake in PTC Therapeutics
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have disclosed a passive beneficial ownership of 8.27% in PTC Therapeutics, Inc., totaling 6,378,000 shares of common stock as of December 31, 2024.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in PTC Therapeutics, Inc.
- As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 6,378,000 shares of PTC Therapeutics, Inc. common stock.
- This ownership represents 8.27% of the company's outstanding common stock, based on 77,125,143 shares reported outstanding as of November 5, 2024, in the Issuer's Form 10-Q.
- Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
- Both reporting persons share voting and dispositive power over all 6,378,000 shares.
- The filing certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's performance or prospects. It merely reports a significant passive stake by an institutional investor.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Disclosure of a significant passive stake by an institutional investor (Armistice Capital, LLC and Steven Boyd) provides transparency regarding the ownership structure of PTC Therapeutics, Inc. This can be viewed as a signal of confidence by a large investor, potentially influencing other investors' perceptions of the stock.
Key Dates
| Date | Description |
|---|---|
| 2024-11-05 | Date as of which 77,125,143 shares outstanding were reported in Issuer's Form 10-Q. |
| 2024-11-07 | Date Issuer's Form 10-Q was filed with the SEC, reporting shares outstanding. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date for beneficial ownership). |
| 2025-02-14 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
PTC Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Passive Investment, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.